Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Dramatic Decline in Female Genital Warts Following HPV Vaccination

By HospiMedica International staff writers
Posted on 05 Jan 2015
The introduction of the Australian national human papillomavirus (HPV) vaccination program has resulted in a significant reduction of genital wart prevalence among young women.

Researchers at the University of Sydney (NSW, Australia) conducted an analysis of 1,175,879 patient encounters with 11,780 general practitioners (GPs). More...
Genital warts management rates were estimated for the periods before and after introduction of the program (pre-program, July 2002-June 2006; post-program, July 2008-June 2012). Control conditions included genital herpes and Gardnerella/bacterial vaginosis in female patients, and genital herpes and urethritis in male patients. Trends in management rates by year were also calculated.

The researchers found that the management rate of genital warts among women potentially covered by the program (i.e., ages 15–27 years) decreased by 61%, from 4.33 per 1,000 encounters in the pre-program period to 1.67 in the post-program period. Trend analysis showed a significant year-on-year reduction in the rate of genital warts management post-vaccination, and a significant increase in the management rate of control conditions per year. For all other age-sex groups there was no significant change in the management rate of genital warts between the pre- and post-program periods. The study was published in the September 2014 issue of PLOS One.

“The results show that the program has been a widespread success. Not only do genital warts cause distress in affected patients, but treatment is at a substantial cost to the health system,” said lead author Christopher Harrison, MSc, of the University of Sydney Family Medicine Research Centre (FMRC). “There was also no significant decrease in other sexually transmitted infections over this period, which means that the decrease in genital warts was likely due to the vaccination program, not a change in the women's behavior.”

Australia was one of the first countries to provide the HPV vaccine free to young women through a national immunization program. The program was initially promoted in terms of prevention of cervical cancer, as HPV types 16 and 18 are known to be the major etiological agents to cervical cancer in around 70% of cases worldwide. However, the quadrivalent vaccine also protects against HPV types 6 and 11, the major causes of genital warts.

Related Links:

University of Sydney



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Immobilization System
Cranial 4Pi Immobilization
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.